The therapy involves taking antibodies from the blood of a person who has recovered from COVID-19 and transfusing those into an active coronavirus infected patient to help kickstart the immune system to fight back the infection.
from COVID-19: No benefit of plasma therapy in reducing mortality risk, says AIIMS Director Dr Randeep Guleria https://ift.tt/3ifY17f
https://ift.tt/eA8V8J
from COVID-19: No benefit of plasma therapy in reducing mortality risk, says AIIMS Director Dr Randeep Guleria https://ift.tt/3ifY17f
https://ift.tt/eA8V8J
No comments:
Post a Comment